

Precision® hERG Recombinant Stable Cell Line

Catalog Number CYL3039 Lot Number See Vial

Contents 2 Vials, 2 x 10⁶ to 4 x 10⁶ in 1 mL

Background Information

The FDA, ICH S7B guidelines set out a non-clinical testing strategy to assess the effects of pharmaceuticals on ventricular repolarisation and proarrhythmic risk. The most common mechanism for this is inhibition of the delayed rectified potassium current IKr. The human ether-à-go-go-related gene (hERG) encodes the potassium ion channel responsible for IKr.

Product Information

Description Recombinant HEK 293 cell line expressing the human ERG (ether-a-go-go related gene) potassium

channel

Family Potassium, Voltage-Gated

Target hERG

| | Target Protein | Accession Number |
|---|----------------|------------------|
| 1 | hERG | U04270 |
| 2 | N/A | N/A |
| 3 | N/A | N/A |
| 4 | N/A | N/A |

Species Human


Host Cell Type HEK 293

Application Electrophysiology assay (conventional and automated patch clamp platforms)

Storage Vials are to be stored in vapor phase of liquid nitrogen

Functional Performance

HEK293 cells expressing hERG were characterized in terms of their pharmacological and biophysical properties using whole-cell patch clamp techniques.



Electrophysiology Method MPC

Reference Agonist

Reference Antagonist Cisapride

Antagonist IC₅₀ (µM)

1

Generated on: June 29, 2020



Passage Stability

This cell line has been confirmed to be stable through at least 12 passages with no significant drop in assay window or change in pharmacology.

Mycoplasma Testing

This lot was tested and found to be free of mycoplasma contamination. Data available upon request.

Notes

Additional functional (pharmacological and electrophysiological) validation on multiple platforms is available upon request.

Additional Ligand Information

Control Compound Cisapride

Vendor Name: Sigma-Aldrich

Vendor Catalog No. C4740

Additional Background Information

N/A

Ordering: +1.510.979.1415 option 4 or e-mail CustomerServiceDRX@eurofins.com Technical support: +1.510.979.1415 option 5 or e-mail DRX_SupportUS@eurofinsUS.com General product information: www.discoverx.com

Limited Use License Agreement

These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License.

Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.

Generated on: June 29, 2020